Qingdao Vland Biotech INC. Stock price

Equities

603739

CNE100003GX8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
11.64 CNY -3.08% Intraday chart for Qingdao Vland Biotech INC. +5.15% -23.52%
Sales 2023 * 1.28B 178M Sales 2024 * 1.46B 202M Capitalization 2.95B 407M
Net income 2023 * 116M 16.05M Net income 2024 * 136M 18.81M EV / Sales 2023 * 2.29 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 2.02 x
P/E ratio 2023 *
25.1 x
P/E ratio 2024 *
21.6 x
Employees 1,590
Yield 2023 *
1.8%
Yield 2024 *
2.23%
Free-Float 32.37%
More Fundamentals * Assessed data
Dynamic Chart
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Qingdao Vland Biotech Forms Chinese JV With Germany’s Evonik MT
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Qingdao Vland Biotech INC. completed the acquisition of 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders. CI
Qingdao Vland Biotech Acquires 51% of Runbot Biotechnology for 91.8 Million Yuan MT
Qingdao Vland Biotech INC. signed a share transfer agreement to acquire a 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders for CNY 91.8 million. CI
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Qingdao Vland Biotech's Joint Venture to Invest Up to 400 Million Yuan for Probiotic Food Plant MT
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Weifang Weizhilan Biological Technology Co., Ltd. announced that it expects to receive CNY 182.888 million in funding from Qingdao Vland Biotech INC., Archer Daniels Midland Singapore Pte Ltd. CI
More news
1 day-3.08%
1 week+5.15%
Current month+14.91%
1 month+8.68%
3 months-26.70%
6 months-17.03%
Current year-23.52%
More quotes
1 week
10.76
Extreme 10.76
12.27
1 month
9.75
Extreme 9.75
12.27
Current year
7.70
Extreme 7.7
15.17
1 year
7.70
Extreme 7.7
18.26
3 years
7.70
Extreme 7.7
20.52
5 years
7.70
Extreme 7.7
30.54
10 years
7.70
Extreme 7.7
30.54
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 14-05-11
Director of Finance/CFO 47 17-05-19
Director/Board Member 69 17-05-19
Members of the board TitleAgeSince
Director/Board Member 69 17-05-19
Director/Board Member 54 11-05-19
Director of Finance/CFO 47 17-05-19
More insiders
Date Price Change Volume
24-03-27 11.64 -3.08% 14,815,200
24-03-26 12.01 +6.38% 17,716,570
24-03-25 11.29 +3.58% 7,186,180
24-03-22 10.9 -1.80% 3,184,200
24-03-21 11.1 +0.27% 3,331,720

End-of-day quote Shanghai S.E., March 26, 2024

More quotes
Qingdao Vland Biotech Co., Ltd. is a China-based company which mainly develops, produces and sells enzyme preparations, micro-ecology and animal health products. The Company's main products are enzyme preparations, micro-ecology and animal health products, such as feed enzymes, industrial enzymes, food enzymes, plant micro-ecological preparations, veterinary chemicals and veterinary drugs. The Company's products are mainly used in the washing, textile, food, feed, paper, energy and pharmaceutical industries. The Company mainly distributes its products in China and overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
11.64
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Qingdao Vland Biotech INC. - Shanghai S.E.